click enter text
full postview rev in-lin ep beat
report financi result tuesday open
revenu us consensu ep beat consensu
estim
first-tim non-gaap ep guidanc given pharma-onli
busi w/o elanco anim health unit encompass consensu
estim guidanc item given previous
make small revenu ep revis lt growth remain
bodi report full analysi
inform us/eu stock cover see global
 april issu monthli controversi report
trade fundament data
upsid target
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
tuesday market open
report result in-lin revenu higher ep vs consensu
saw share drop
overal impress report reason result coupl import key product weak
trulic taltz matter two biggest futur growth driver provid first-tim ep
guidanc follow divestitur elanco encompass consensu previous compani
provid ex-elanco guidanc element unchang apart financi result
rel quiet quarter major updat confer call increment info
provid major updat tanezumab would yet say compound dead view
long-term growth profil remain compel one stock consensu buy valuat
alreadi encompass high investor expect peer-perform rate favor pre-dispos
toward futur growth prospect
inform us/eu stock cover see april issu monthli
term sale ep exhibit
revenu lower vs consensu in-lin
non-gaap ep modestli higher vs consensu sg
 higher expect due launch expens higher invest late-stag asset
respect partial off-set lower tax rate higher incom
trulic lower consensu miss impact
inventori work-down lower realiz price taltz lower vs consensu
increas demand off-set lower realiz price
term guidanc exhibit
revenu maintain new non-gaap ep slightli
encompass consensu reiter oper margin least vs
forecast
pipelin larg insignific phase loss oncolog includ prexasertib ovarian cancer
recent highlight lli guidanc meet
revenu increas ep increas
page
revenu estim chang rang ep estim
decreas depend year
ep compound-annual-growth-rate ep compound-annual-growth-rate decreas slightli still well peer
price target increas vs prior repres unchang
gener prepar remark note
us price declin
trulic almost share us fast grow market
empagliflozin recent refus file snda presum type dm
 trulic price think net price one-tim impact
remain excit share class grow see price pressur across diabet
categori price compar
 insulin competit includ admelog share gain made manag
medicaid outsid area gain much traction continu view
interchang immin like happen wolf comment san say expect
interchang earli earliest gener minim risk past
question topic
 rewind data view wow game-chang data prescrib present
ada continu say excit note investor call ada would say
whether wow data howev
 rewind driven high-risk patient generaliz broader popul
would provid addit inform
 trulic clarifi magnitud inventori work-down ye contribut around
differ volum report us sale
 tirzepatid obes trial detail provid mention obes
nash opportun obes provid detail time need engag fda
titrat data ada
page
 price much lower net price relat donut hole versu
someth els becom import saw small impact account
perspect materi realli
note approv china partner innov broad develop program
 data set watch remain excit erk inhibitor coupl
present data cyramza egfr data submit approv
later year
 updat think pegilodecakin remain confid greatest opportun lung renal
 verzenio updat term new data come data later data
adjuv trial read
 view ret inhibitor versu competitor registr data
 thought abbv skyrizi potenti impact taltz note data expect believ
taltz continu grow remind data vs later year
 olumi updat believ first atop derm oral jak recal first two
studi posit read year posit submit approv
 taltz first line market share psoriasi expect grow post introduct
derm share psoriasi reiter confid trial vs tremfya
high confid continu growth right forc step-through anti-tnfi
olumi clarifi whether file also updat dose comment
pfe xeljanz safeti data believ us uptak slow steadi pursu
competit environ still studi may make market high-dos
xeljanz safeti find say seen signal product
emgal new brand share meaning sale contribut begin
 emgal price demand high market gain free good impact sale
claim reimburs
 clarif payer environ recept payer overal mani restrict
place primari care prescrib access
page
 tanezumab dead answer state enter collabor
big unmet need continu analyz result recent disclosur discuss
regul come month help decid next step wolf comment think dead
regulatori perspect commerci one view long time
make big bet four new area ret inhibitor loxo regulatori submiss end
year btd three ret-rel indic tirzepatid expect level efficaci seen
product pegilodekakin see singl activ rcc nsclc data year mirikizumab
especi excit ibd cd data
 might rebat reform impact lli net price esp diabet impact realli patient
level experi lower price view pretti neutral overal plan
implement
 rebat chang reform rule impact product reli volume-bas rebat wont
open formulari commerci ye think help open access
expect chang implement commerci part biggest impact ta
expect improv oper margin remain quarter
 oper margin reach mid high time goal remain describ
previous beyond would expect expans continu would quantifi
page
exhibit show compani report actual result vs estim consensu
exhibit result vs wr estim consensu
page
exhibit summar lli financi guidanc vs estim
exhibit guidanc vs wr estim old new exclud elanco
page
oldnewprior wolf estimatewolf bgross marginapprox bother meffect tax rateapprox oper incom approx pharma guidancewr estim
exhibit captur chang forecast
exhibit chang wr model
page
exhibit show incom statement product revenu summari balanc sheet/cash flow
page
incom statement incom loss cont op dilut share growth outstand
page
product revenu emgal galcanezumab anti-cgrp growth share tradjenta basaglar biosimilar share jardianc trulic women endocrinolog growth diabet alimta cyramza gastric lartruvo olaratumab verzenio abemaciclib erbitux total taltz ixekizumab olumi baricitinib jak total total earli stage factor- total
exhibit wr eli lilli balanc sheet cash flow statement
page
summari statement incom reconcil incom tax cash provid oper tax chang oper asset defer compens impair net in-process technolog net cash provid sale in-process product paid acq/loan cash provid use invest stock capit chang short term issuanc long term repay long-term cash provid use financ exchang rate cash increas decreas end balanc sheet cash equival short term properti plant goodwil current term non-curr paid-in comprehens treasuri stock sharehold liabil sharehold
